Hansen Medical Announces Second Quarter 2012 Results Conference Call
27 7월 2012 - 9:00PM
Marketwired
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in
intravascular robotics, today announced that it will release its
financial and operating results for the second quarter ended June
30, 2012 after market close on Wednesday, August 8, 2012.
Bruce Barclay, President and Chief Executive Officer, will host
a conference call at 5:00 p.m. ET (2:00 p.m. PT) on August 8, 2012
to discuss the company's results. The call may be accessed by
dialing 877-941-8416 (480-629-9808 for international callers) and
via the Internet in the Investor Relations section of Hansen
Medical's website at www.hansenmedical.com. Please go to the
website at least 15 minutes early to register, download and install
any necessary audio software. Following the call, a webcast replay
will be available on Hansen Medical's website, and an audio replay
will also be available by calling 877-870-5176 (858-384-5517 for
international callers) and entering the access code 4552153. The
audio replay will be available through August 15, 2012.
About Hansen Medical, Inc. Hansen Medical,
Inc., based in Mountain View, California, is the global leader in
intravascular robotics, developing products and technology designed
to enable the accurate positioning, manipulation and control of
catheters and catheter-based technologies. The Company's Magellan™
Robotic System, NorthStar™ Robotic Catheter and related
accessories, which are intended to facilitate navigation to
anatomical targets in the peripheral vasculature and subsequently
provide a conduit for manual placement of therapeutic devices, have
undergone both CE marking and 510(k) clearance and are commercially
available in the European Union, and the U.S. In the European
Union, the Company's Sensei® X Robotic Catheter System and Artisan
Control Catheter are cleared for use during electrophysiology (EP)
procedures, such as guiding catheters in the treatment of atrial
fibrillation (AF), and the Lynx® Robotic Ablation Catheter is
cleared for the treatment of AF. This robotic catheter system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the US the Company's Sensei X Robotic
Catheter System and Artisan Control Catheter were cleared by the
U.S. Food and Drug Administration for manipulation and control of
certain mapping catheters in EP procedures. In the United States,
the Sensei System is not approved for use in guiding ablation
procedures; this use remains experimental. The U.S. product
labeling therefore provides that the safety and effectiveness of
the Sensei X System and Artisan Control Catheter for use with
cardiac ablation catheters in the treatment of cardiac arrhythmias,
including AF, have not been established.
Additional information can be found at
www.hansenmedical.com.
Forward-Looking Statements This press
release contains forward-looking statements regarding, among other
things, statements relating to goals, plans, objectives, milestones
and future events. All statements, other than statements of
historical fact, are statements that could be deemed
forward-looking statements, including statements containing the
words "plan," "expects," "potential," "believes," goal,"
"estimate," and similar words. These statements are based on the
current estimates and assumptions of our management as of the date
of this press release and are subject to risks, uncertainties,
changes in circumstances and other factors that may cause actual
results to differ materially from the information expressed or
implied by forward-looking statements made in this press release.
Examples of such statements include statements about, the potential
benefits of our Magellan Robotic System on vascular procedures and
the timing and results of commercializing our Magellan Robotic
System. Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
include, among others: engineering, regulatory and sales challenges
in developing new products and entering new markets; potential
safety and regulatory issues that could slow or suspend our sales;
the uncertain timelines, costs and results of pre-clinical and
clinical trials; the rate of adoption of our systems and the rate
of use of our catheters; the scope and validity of intellectual
property rights applicable to our products; competition from other
companies; our ability to recruit and retain key personnel; our
ability to maintain our remedial actions over previously reported
material weaknesses in internal controls over financial reporting;
the effect of credit, financial and economic conditions on capital
spending by our potential customers; our ability to manage expenses
and obtain additional financing; and other risks more fully
described in the "Risk Factors" section of our Quarterly Report on
Form 10-Q for the quarter ended March 31, 2012 filed with the SEC
on May 7, 2012 and the risks discussed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release.
We undertake no obligation to revise or update information herein
to reflect events or circumstances in the future, even if new
information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries. Rheos neo is a trademark of CVRx,
Inc.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting,
Inc. Brian Ritchie 212.850.5683 Email Contact John Capodanno
212.850.5705 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024